The United Kingdom and the United States have announced a landmark bilateral deal that will guarantee no import taxes on UK drug products entering the American market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to increase spending on pharmaceuticals through the public health system. This pledge secures that import taxes on these vital goods will remain at zero for a duration of 36 months.
This agreement follows recent threats to significantly raise duties on patented drug imports, with increases mentioned reaching one hundred percent.
"This deal with the Britain bolsters the worldwide climate for cutting-edge drugs and brings much-needed balance to U.S.–U.K. drug exports," an announcement declared.
Trade Significance
Pharmaceuticals represent one of the UK's biggest exports to the US, which is by far the largest destination for large companies like GSK and AstraZeneca.
Export figures indicate that in the one-year period leading up to last September, the UK sold medicines totaling over eleven billion pounds to the US. This figure accounted for 17.4% of all goods exports in that span.
"This guarantee protects work, boosts funding and paves the way for the UK to emerge as a worldwide center for medical research," a minister stated.
Key NHS Changes
The agreement involves several specific changes from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new therapies to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to double total NHS spending on drugs from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at fifteen percent. In the past, refunds exceeded twenty percent.
Industry Background
The deal follows a ongoing dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
This friction were exacerbated by claims that American patients were paying significantly more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or cancelled, while substantial expansions have been directed toward US facilities.
The Science Minister publicly accepted that the NHS must spend more on drugs, noting that its expenditure on drugs had decreased as a proportion of its total funding over the last ten years.
